期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 15, 期 -, 页码 S91-S93出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2015.02.031
关键词
New treatment of secondary AML
Effective treatment options for adults with therapy-related AML continues to be an area of unmet need. Genetic and molecular changes within these leukemias confer resitance to standard chemotherapy regimens. Emerging develpmental therapeutics in this area has focused on several approaches. These include; novel delivery of chemotherapy as well as newer DNA-damaging agents delivered through antibody-drug conjugates, increased use of hypomethylating agents, and molecularly-directed small molecules against specific mutations commonly occuring in secondary AML. Results of this efforts are encouraging, but to date, no clear improvements have been demonstrated in this most difficult to treat population. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据